Company News: Pfizer and GSK

Share this article:

Pfizer said its full-year 2009 revenues rose 4% to $50 billion, with US revenues up 7% over 2008 to $21.7 billion and international revenues up 1% to $28.3 billion. Fourth-quarter US revenues were up 42% compared to Q4 2008, while international revenues were up 28%.

GlaxoSmithKline announced its annual results, showing 3% sales growth for 2009, with sales from “white pills in western markets” down to 30% of full-year sales from 2008's 36%. Emerging markets sales were up 20%, while sales in Japan were up 22% and consumer healthcare product sales rose 7%. The company also announced the launch of a new specialist unit to research and develop drugs for rare diseases.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.